12:00 AM
Mar 27, 2000
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Warner-Lambert sales and marketing update

At the FDA's request, WLA discontinued sales of its Rezulin troglitazone to treat Type II diabetes but said it still believes the benefits of the product outweigh its risks of...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >